LSTA — Lisata Therapeutics Balance Sheet
0.000.00%
- $21.36m
- -$0.86m
- $1.00m
- 21
- 24
- 64
- 28
Annual balance sheet for Lisata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 34.6 | 95 | 69.2 | 50.5 | 31.2 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | — | 0.9 |
| Prepaid Expenses | |||||
| Total Current Assets | 35.3 | 96.2 | 71.9 | 53.9 | 34.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.631 | 0.786 | 0.783 | 0.483 | 0.21 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 36 | 97 | 73 | 54.7 | 35 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 3.51 | 4.52 | 6.38 | 6.59 | 5.61 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.51 | 4.75 | 6.46 | 6.55 | 5.43 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 32.5 | 92.3 | 66.6 | 48.1 | 29.6 |
| Total Liabilities & Shareholders' Equity | 36 | 97 | 73 | 54.7 | 35 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |